Davidson J R
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, N.C. 27710, USA.
J Clin Psychiatry. 1997;58 Suppl 2:26-8; discussion 29-31.
Over the past 15 years, benzodiazepines have been used successfully to treat panic disorder with agoraphobia, but not without some controversy. Efficacy and side effect data from the principal benzodiazepine outcome studies of panic disorder demonstrate that alprazolam, lorazepam, and clonazepam are all clinically effective. Clonazepam has several advantages over other benzodiazepines and can be considered a first-line agent for panic disorder. Benzodiazepines in general are therapeutically effective for a broad range of panic disorder symptoms. Their effect is rapid and maintained without dose increase over a 7- to 8-month period. Discontinuation-related difficulties can occur in a considerable number of patients, but these can be decreased in several ways.
在过去15年里,苯二氮䓬类药物已成功用于治疗伴有广场恐惧症的惊恐障碍,但并非没有争议。惊恐障碍主要苯二氮䓬类药物疗效研究的疗效和副作用数据表明,阿普唑仑、劳拉西泮和氯硝西泮在临床上均有效。氯硝西泮相对于其他苯二氮䓬类药物有几个优点,可被视为惊恐障碍的一线用药。一般来说,苯二氮䓬类药物对广泛的惊恐障碍症状具有治疗效果。它们起效迅速,且在7至8个月的时间内无需增加剂量就能维持疗效。相当一部分患者可能会出现与停药相关的问题,但可以通过几种方式减少这些问题。